Re-irradiation and hyperthermia after surgery for recurrent breast cancer

Linthorst, Marianne; Geel, A.N. van; Baaijens, Margreet H.A.; Ameziane, A.; Ghidey, Wendimagegn; Rhoon, Gerard C. van; Zee, Jacoba van der

doi:10.1016/j.radonc.2013.05.010

Cited by 66 publications

(74 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, Linthorst et al [38] evaluated the combined treatment and concluded that RTHT can offer good local control without serious toxicity. RTHT was applied in 198 patients suffering from breast cancer recurrences.…”

Section: Resultsmentioning

confidence: 99%

Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data

et al. 2015

View full text Add to dashboard Cite

Background: Hyperthermia has been included in the 2013 National Comprehensive Cancer Network (NCCN) guidelines as an option for the treatment of breast recurrences. The purpose of this article is to demonstrate the important role of hyperthermia as a therapeutic modality by presenting clinical trials on this subject carried out in the last decades. Materials and Methods: All relevant trials published since 1987 were retrieved from Medline and reviewed. Results: Results show that the addition of hyperthermia to radiotherapy and/or chemotherapy for the treatment of breast cancer enhances treatment response and can increase local control. Conclusion: Further studies are required to evaluate potential benefits of hyperthermia in the treatment of other kinds of superficial tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data

et al. 2015

View full text Add to dashboard Cite

show abstract

“…HT is the use of elevated temperature to the degrees of [40][41][42][43][44] • C for 30-60 min for its antitumoral effect. Hallmarks of HT were nicely summarized by Issels et al [31].…”

Section: Hyperthermiamentioning

confidence: 99%

“…• C but normal tissue toxicity impedes its role above [44][45] • C in clinical setting. Cells struggle with various types of stress by upregulation of specific proteins, which are heat shock proteins in the case of HT and are responsible for transient thermotolerance which is an unwanted side effect that could be overcome by prolonged heating [32,33].…”

Section: Hyperthermiamentioning

confidence: 99%

“…Toxicity related to HT includes generally second-and third-degree skin and subcutaneous burns, which are usually self-limited [44]. In a prospective randomized trial of superficial tumors (<3 cm depth) comparing RT versus HT combined with RT, almost half of the patients (46%) experienced HT-related thermal burns but only one of whom was grade 3 and healed with conservative measures [41].…”

Section: Hyperthermiamentioning

confidence: 99%

“…Evidence in adjuvant setting after surgery for recurrent disease Management of subclinical disease was investigated in aforementioned randomized trial in a setting of no prior RT [49] and apart from this, Linthorst et al, retrospectively reviewed 198 patients with recurrent BC treated with re-RT and HT [44]. The indication for combined therapy was microscopic residual disease following resection or systemic therapy for 91 (46%) patients and was elective purposes in areas at high risk for 107 (54%) patients.…”

Section: Ht For Irresectable Bc Recurrencesmentioning

confidence: 99%

See 2 more Smart Citations

Hyperthermia and Radiotherapy Combination for Locoregional Recurrences of Breast Cancer: A Review

Arslan

Özdemir

Şendur

et al. 2017

Breast Cancer Manag.

View full text Add to dashboard Cite

Practice pointsr Locoregional breast recurrences still occur in more or less 5-20% of patients despite receiving adjuvant radiotherapy. r Resection alone provides limited local control with approximately 33% at 5-years compared to 42% with resection plus other oncologic treatments necessitating curative intent multidisciplinary approach. r Hyperthermia (HT) is the use of elevated temperature to the degrees of 40-44 • C for 30-60 min. The addition of HT to ionizing radiation results in a synergistic effect called radiosensitization. r Toxicity related to HT includes generally second-and third-degree skin and subcutaneous burns, which are usually self-limited making this combination a favorable easy to use modality. r Data addressing the use of HT in locoregional breast recurrences (LRBR) is well-validated and includes randomized trials and meta-analysis. r Thermoradiotherapy enhances local control rates in LRBR with minimal acute, late morbidity and is even more effective in previously irradiated group. r Two trials conducted by European Society for Hyperthermic Oncology will further clarify the multimodal treatment with chemotherapy in R1/R2 resection and neoadjuvant use of thermoradiotherapy.Breast cancer is a second common form of malignancy and is one of the leading causes of mortality among cancer patients across the world. Locoregional recurrence occurs in 5-20% of patients despite upfront treatment. Local therapy (surgery plus minus re-irradiation) with or without systemic therapy is generally recommended for management. Local control rates vary; months to years, but a significant percentage lives 5 years. Therefore, treatment strategies to increase response rates are significant. Hyperthermia is one of the most potent radiosensitizers and data from meta-analysis and randomized trials support its use with radiotherapy. This study reviews the biologic rationale and clinical evidence about concomitant use of hyperthermia and radiotherapy in locally-recurrent breast cancer patients. Chest wall or whole breast irradiation with or without regional nodal sites is indicated after modified radical mastectomy and breast conserving surgery (BCS), respectively. Although adjuvant radiotherapy (RT) effectively reduces locoregional recurrences, data from randomized trials have demonstrated that this type of recurrences still occur in more or less 5-20% of patients despite receiving adjuvant RT after surgery (mastectomy or BCS) [1][2][3][4][5][6].Although locally-recurrent breast cancer (LRBC) is usually accompanied by concurrent or subsequent distant metastases [3,7,8], a significant percentage, more than 50% live 5 years [9]. In a retrospective study of 145 patients with isolated locoregional recurrence of breast cancer following modified radical mastectomy without evidence of distant metastases, 5-year survival rates were 42% overall but it was 100% for a highly favorable subgroup [10].

show abstract

Clinical Applications of Hyperthermia

Mishra,

Mandal

2023

The Application of Heat in Oncology

View full text Add to dashboard Cite

Re-irradiation and hyperthermia after surgery for recurrent breast cancer

Cited by 66 publications

References 18 publications

Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data

Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data

Hyperthermia and Radiotherapy Combination for Locoregional Recurrences of Breast Cancer: A Review

Clinical Applications of Hyperthermia

Contact Info

Product

Resources

About